Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe |
| Completed | 3 | 678 | US, Europe, RoW | Canagliflozin, Placebo, Sitagliptin | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 08/11 | 03/12 | | |
|
|
|
|
|
|
|
| Completed | 3 | 469 | US, Europe, RoW | Canagliflozin, Placebo, Metformin, Sulphonylruea | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 09/11 | 04/12 | | |
|
|
|
|
|
NCT01106677: The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial) |
|
|
| Completed | 3 | 1284 | US, Europe, RoW | Placebo, Canagliflozin, Sitagliptin, Metformin immediate release | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 10/11 | 05/12 | | |
|
|
|
| Completed | 3 | 344 | US, Canada, Europe, RoW | Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 11/11 | 07/12 | | |
|
|
|
NCT01106651 / 2010-018411-15: A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 716 | US, Canada, Europe, RoW | Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 11/11 | 05/13 | | |
|
| Completed | 3 | 1452 | US, Canada, Europe, RoW | Glimepiride, sulfonylurea, Canagliflozin (JNJ-28431754), Metformin | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 12/11 | 01/13 | | |
|
|
|
|
|
|
|
|
|
|
NCT01064414 / 2009-017136-40: An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment |
|
|
| Completed | 3 | 272 | US, Canada, Europe, RoW | Canagliflozin, Placebo | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2, Renal Insufficiency | 12/11 | 08/12 | | |
|
|
|
|
| Completed | 3 | 756 | US, Canada, Europe, RoW | Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 03/12 | 03/12 | | |
|
|
|
|
NCT01413204: Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes |
|
|
| Completed | 3 | 272 | Japan | TA-7284 Low, TA-7284 High, Placebo | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 08/12 | 08/12 | | |
NCT01387737: Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 1299 | Japan | TA-7284-Low, TA-7284-High | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 11/12 | 12/12 | | |
NCT01381900: A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea |
|
|
| Completed | 3 | 678 | RoW | Placebo, Canagliflozin 100mg, Canagliflozin 300mg, Metformin, Sulphonylurea | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 11/12 | 11/12 | | |
NCT01809327 / 2011-000400-17: A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise |
|
|
| Completed | 3 | 1186 | US, Europe, RoW | Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 12/14 | 12/14 | | |
NCT02354235: Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) |
|
|
| Completed | 3 | 138 | Japan | Teneligliptin, Tenelia, MP-513, Canagliflozin, Canaglu, TA-7284, Placebo | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 01/16 | 01/16 | | |
NCT02354222: Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin) |
|
|
| Completed | 3 | 154 | Japan | Canagliflozin, Canaglu, TA-7284, Teneligliptin, Tenelia, MP-513, Placebo | Mitsubishi Tanabe Pharma Corporation | Type 2 Diabetes Mellitus | 02/16 | 02/16 | | |
| Completed | 3 | 4330 | Canada, US, Europe, RoW | Placebo, Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg | Janssen Research & Development, LLC, The George Institute for Global Health, Australia | Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors | 02/17 | 02/17 | | |
|
|
|
|
|
|
|